The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive impact of PD-L1-expressing circulating tumor cells in NSCLC patients treated with nivolumab.
 
Ryota Shibaki
No Relationships to Disclose
 
Yasuhiro Koh
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Illumina; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Raindance Technologies
Consulting or Advisory Role - Tosoh Corporation
Research Funding - Chugai Pharma; Daiichi Sankyo; Novartis
 
Hiroaki Akamatsu
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Kazuki Kurita
No Relationships to Disclose
 
Satomi Yagi
Employment - Hitachi Chemical
 
Kuninobu Kanai
No Relationships to Disclose
 
Atsushi Hayata
No Relationships to Disclose
 
Nahomi Tokudome
No Relationships to Disclose
 
Masayuki Higuchi
Employment - Hitachi Chemical
 
Hisashige Kanbara
Employment - Hitachi Chemical
 
Keiichiro Akamatsu
No Relationships to Disclose
 
Hiroki Ueda
No Relationships to Disclose
 
Masanori Nakanishi
No Relationships to Disclose
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Fujifilm; Janssen; Kyorin; Kyowa Hakko Kirin; Lilly Japan; M3; Merck Sharp & Dohme; Nippon Boehringer Ingelheim; Novartis; Oncology; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma; Merck Sharp & Dohme; Nippon Boehringer Ingelheim; Ono Pharmaceutical
Research Funding - AC Medical; AstraZeneca Japan; Daiichi Sankyo; Kyorin; Kyowa Hakko Kirin; Maruho; Meiji Seika Kaisha; Merck Sharp & Dohme; Nippon Boehringer Ingelheim; Ono Pharmaceutical; PAREXEL; Pfizer; Quintiles; Shionogi; Taiho Pharmaceutical